Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.31 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876886 | 0.88 | SLC28A3 (0.37) | SLC28A3F10 | |
| SCHEMBL8271555 | 0.88 | SLC28A3 (0.37) | SLC28A3F10 | |
| SCHEMBL14269790 | 0.88 | SLC28A3 (0.37) | SLC28A3F10 | |
| SCHEMBL8271556 | 0.88 | SLC28A3 (0.37) | SLC28A3F10 | |
| SCHEMBL8271553 | 0.88 | SLC28A3 (0.37) | SLC28A3F10 | |
| SCHEMBL4877826 | 0.87 | SLC28A3 (0.35) | SLC28A3F10NPC1USP2TNNI3 | |
| SCHEMBL4870354 | 0.87 | SLC28A3 (0.35) | SLC28A3F10L3MBTL1 | |
| SCHEMBL6778930 | 0.85 | TSHR (0.38) | RAB9A | |
| SCHEMBL16436970 | 0.85 | TSHR (0.38) | RAB9A | |
| SCHEMBL19699426 | 0.85 | TSHR (0.38) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794507-B2 | Compounds that inhibit factor Xa activity | MORPHOCHEM AG (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030153510-A1 | Novel compounds inhibiting factor xa activity | CAPPI MICHAEL W (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1311473-A2 | NOVEL COMPOUNDS INHIBITING FACTOR XA ACTIVITY | Morphochem AG (DE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016312-A2 | NOVEL COMPOUNDS INHIBITING FACTOR XA ACTIVITY | MORPHOCHEM AG (DE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153510-A1 | Novel compounds inhibiting factor xa activity | SERPINC1, F11, TFPI | SLC28A3 2143/4885F10 6/4885NPC1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.